By Thomas M. Burton and Peter Loftus

Johnson & Johnson's single-dose Covid-19 vaccine was effective "across demographic subgroups" in a late-stage study, U.S. Food and Drug Administration scientists plan to tell a panel of medical specialists meeting Friday to evaluate the shot.

The FDA officials, in other testimony prepared for the advisory committee, also said the agency plans to continue studying the vaccine to assess the its efficacy across specific populations, the duration of the protection against Covid-19 provided by the shot and its potency against new strains of the virus.

The committee's meeting is the final step before U.S. health regulators decide whether to authorize use of a third shot. The decision is expected Saturday.

The panel, which includes 22 medical specialists in fields like internal medicine, pediatrics, vaccines and epidemiology, regularly advises the U.S. Food and Drug Administration about experimental vaccines. It voted to recommend shots from Pfizer Inc. and partner BioNTech SE and Moderna Inc. before the agency authorized them in December.

In other testimony prepared for the panel, the U.S. Centers for Disease Control and Prevention said preliminary results of safety data for the Pfizer-BioNTech and Moderna vaccines showed no statistically significant increased risk of adverse events among people who got those shots.

During the all-day public meeting, representatives from the FDA and J&J will discuss the safety and effectiveness of the company's vaccine in a 44,000-plus subject study, according to an agenda, as well as how effective the J&J vaccine is in preventing new cases caused by variants.

The give-and-take of questions and answers can be valuable in bolstering public confidence in the shot, FDA officials say.

The vaccine was 66% effective at protecting people from moderate to severe Covid-19, an FDA review found, and even more effective at preventing severe disease alone.

J&J, citing preliminary evidence in an analysis released by the FDA, said the vaccine was 65.5% effective in preventing asymptomatic infections, in a subset of study subjects.

Health authorities have been watching whether Covid-19 shots can stop people without symptoms from transmitting the virus, because the virus has largely been spread by people who were infected but didn't realize it because they had no symptoms.

Rollout of the J&J vaccine doses could add -- by an estimated 20% during March -- to the total number available, as health authorities pick up the pace of vaccinations and try to inoculate enough people as quickly as possible so business, schools and other establishments can fully reopen.

J&J has said it would deliver about 20 million doses for U.S. use by the end of March.

The FDA often convenes public meetings of outside experts to scrutinize experimental drugs, devices and vaccines up for agency approval, in part to boost public acceptance of the products should they be cleared for wide use.

J&J's vaccine appeared to be safe in its pivotal study, the FDA found, aside from being effective.

The vaccine was less effective in South Africa, where a more-transmissible Covid-19 variant has thrived, than in the U.S. J&J is among the companies working on new shots targeting the new strain, which several current vaccines don't appear to work as well against.

J&J's Covid-19 shot was, however, very effective against severe and critical cases in South Africa. The vaccine was 73.1% effective in preventing such cases occurring at least 14 days after vaccination, and 81.7% effective in preventing such cases at least 28 days after vaccination.

Write to Thomas M. Burton at tom.burton@wsj.com and Peter Loftus at peter.loftus@wsj.com

(END) Dow Jones Newswires

02-26-21 1033ET